Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 1;49(2):e20220356.
doi: 10.36416/1806-3756/e20220356. eCollection 2023.

Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion

[Article in English, Portuguese]
Anthony J Esposito  1   2 , Jewel Imani  1 , Shikshya Shrestha  1 , Shefali Bagwe  1 , Anthony M Lamattina  1 , Marina Vivero  3 , Hilary J Goldberg  1 , Ivan O Rosas  4 , Elizabeth P Henske  1 , Souheil Y El-Chemaly  1   5
Affiliations

Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion

[Article in English, Portuguese]
Anthony J Esposito et al. J Bras Pneumol. .

Abstract
in English, Portuguese

Objective: Lymphangioleiomyomatosis (LAM) is a rare, destructive disease of the lungs with a limited number of determinants of disease activity, which are a critical need for clinical trials. FGF23 has been implicated in several chronic pulmonary diseases. We aimed to determine the association between serum FGF23 levels and pulmonary function in a cohort of patients with LAM.

Methods: This was a descriptive single-center study in which subjects with LAM and controls with unreported lung disease were recruited. Serum FGF23 levels were measured in all subjects. Clinical data, including pulmonary function testing, were retrospectively obtained from electronic medical records of LAM subjects. Associations between FGF23 levels and clinical features of LAM were explored via nonparametric hypothesis testing.

Results: The sample comprised 37 subjects with LAM and 16 controls. FGF23 levels were higher in the LAM group than in the control group. In the LAM group, FGF23 levels above the optimal cutoff point distinguished 33% of the subjects who had nondiagnostic VEGF-D levels. Lower FGF23 levels were associated with impaired DLCO (p = 0.04), particularly for those with isolated diffusion impairment with no other spirometric abnormalities (p = 0.04).

Conclusions: Our results suggest that FGF23 is associated with pulmonary diffusion abnormalities in LAM patients and elicit novel mechanisms of LAM pathogenesis. FGF23 alone or in combination with other molecules needs to be validated as a biomarker of LAM activity in future clinical research.

Objetivo:: A linfangioleiomiomatose (LAM) é uma doença rara e destrutiva dos pulmões com um número limitado de determinantes da atividade da doença, que são uma necessidade crítica para ensaios clínicos. O FGF23 já foi implicado em várias doenças pulmonares crônicas. O nosso objetivo foi determinar a associação entre os níveis séricos de FGF23 e a função pulmonar em uma coorte de pacientes com LAM.

Métodos:: Estudo descritivo unicêntrico no qual foram recrutados indivíduos com LAM e controles com doenças pulmonares não declaradas. Os níveis séricos de FGF23 foram medidos em todos os indivíduos. Os dados clínicos, incluindo testes de função pulmonar, foram obtidos retrospectivamente a partir dos prontuários eletrônicos dos indivíduos com LAM. As associações entre os níveis de FGF23 e as características clínicas da LAM foram exploradas por meio do teste de hipóteses não paramétrico.

Resultados:: A amostra incluiu 37 indivíduos com LAM e 16 controles. Os níveis de FGF23 foram mais altos no grupo LAM do que no grupo controle. No grupo LAM, níveis de FGF23 acima do ponto de corte ideal distinguiram 33% dos indivíduos com níveis não diagnósticos de VEGF-D. Níveis mais baixos de FGF23 estavam associados à DLCO comprometida (p = 0,04), particularmente naqueles com comprometimento isolado da difusão e sem outras alterações espirométricas (p = 0,04).

Conclusões:: Nossos resultados sugerem que o FGF23 está associado a alterações na difusão pulmonar em pacientes com LAM e potencialmente indicam novos mecanismos de patogênese da LAM. O FGF23 isoladamente ou em combinação com outras moléculas precisa ser validado como um biomarcador da atividade da LAM em futuras pesquisas clínicas.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: None declared.

Figures

Figure 1
Figure 1. Circulating FGF23 levels differentiate subjects with lymphangioleiomyomatosis (LAM) from healthy controls. In A, serum FGF23 levels in control (N = 16) and LAM (N = 37) subjects. In B, ROC curve assessing the efficiency of serum FGF23 levels in discriminating subjects with LAM from controls. LR+: positive likelihood ratio. *p < 0.05.
Figure 2
Figure 2. Circulating FGF23 levels are lower in subjects with lymphangioleiomyomatosis (LAM) and pulmonary diffusion abnormalities. In A, serum FGF23 levels in LAM subjects (N = 36) with or without a diffusion defect. In B, serum FGF23 levels in LAM subjects (N = 36) with or without an isolated diffusion defect. *p < 0.05.
See this image and copyright information in PMC

References

    1. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006;27(5):1056–1065. doi: 10.1183/09031936.06.00113303. - DOI - PubMed
    1. Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, Brooks PG. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med. 2001;164(4):669–671. doi: 10.1164/ajrccm.164.4.2101154. - DOI - PubMed
    1. Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 2013;144(2):578–585. doi: 10.1378/chest.12-2813. - DOI - PubMed
    1. Henske EP, Józwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035–16035. doi: 10.1038/nrdp.2016.35. - DOI - PubMed
    1. Cui Y, Steagall WK, Lamattina AM, Pacheco-Rodriguez G, Stylianou M, Kidambi P. Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Res. 2017;77(6):1492–1502. doi: 10.1158/0008-5472.CAN-16-2755. - DOI - PMC - PubMed